Most Oncologic Drugs Advisory Committee members took issue with the lack of dosing optimization and the lack of US patient ...

British biopharmaceutical company GlaxoSmithKline will lay off 150 employees in its Cambridge operations by the end of March ...

Co-authors reported grants from Takeda Pharmaceuticals and UCB, consulting for GlaxoSmithKline, and personal fees from the ...

Roche and Genentech were unable to sufficiently demonstrate the benefit of using Columvi in an earlier treatment setting for ...

Shares of healthcare tech company Privia Health Group (NASDAQ:PRVA) jumped 3.4% in the morning session as investors ...

Shares of medical technology company Enovis Corporation (NYSE:ENOV) jumped 3.3% in the morning session after the stock gained ...

Concentra Biosciences is living up to its reputation of buying beleaguered biotechs, this time swooping in to grab iTeos ...

The new week brings with it fresh attempts for several markets to hit new highs, with the FTSE 100 pushing around the 9,000 ...

The path to market for Roche’s astegolimab became more uncertain after the investigational antibody failed to significantly ...

"While COPD remains the third leading cause of death worldwide, patients and families have limited treatment options for ...

ViiV Healthcare has announced steps to widen access to a sought-after HIV medicine in low- and middle-income countries, ...

iTeos Therapeutics has agreed to be acquired by privately held Concentra Biosciences in a deal initially worth roughly $385 million. iTeos on Monday said Concentra will pay nearly $10.05 a share in ...